{"id":2007,"date":"2023-06-19T08:52:34","date_gmt":"2023-06-19T12:52:34","guid":{"rendered":"https:\/\/happylungsproject.org\/?p=2007"},"modified":"2026-03-02T10:53:35","modified_gmt":"2026-03-02T15:53:35","slug":"ellipses-pharma-presents-encouraging-data-on-next-generation-selective-ret-inhibitor-ep0031-at-asco-2023-annual-conference","status":"publish","type":"post","link":"https:\/\/happylungsproject.org\/ellipses-pharma-presents-encouraging-data-on-next-generation-selective-ret-inhibitor-ep0031-at-asco-2023-annual-conference\/","title":{"rendered":"Ellipses Pharma presents \u2018encouraging\u2019 data on selective RET inhibitors"},"content":{"rendered":"[vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none” shape_type=””][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/1″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][divider line_type=”No Line” custom_height=”20″][vc_column_text]\n
\n
\n
\n
\n
\n
\n

Data of the Phase 1 Study of KL590586 (EP0031\/A400), presented at ASCO, reported preliminary efficacy and safety for a total of 109 patients. EP0031\/A400 is a potent next generation specific RET inhibitor with broad activity against common RET fusions and mutations, including solvent front resistance mutations. Therefore, EP0031\/A400 may have the potential to overcome resistance to first generation RET inhibitors.<\/p>\n

Safety: A400\/EP0031 was generally well tolerated with most treatment-related adverse events grade 1-2.<\/p>\n

View the full informational EP0031 PDF here<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n[\/vc_column_text][divider line_type=”No Line” custom_height=”20″][image_with_animation image_url=”2013″ image_size=”full” animation_type=”entrance” animation=”None” animation_movement_type=”transform_y” hover_animation=”none” alignment=”” img_link_large=”yes” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default”][vc_column_text]\n

\n
\n
\n
\n
\n
\n
\n
\n
\n

Efficacy: In the overall RET-altered tumor population, patients who received A400\/EP0031 at doses between 40 and 120mg once a day had an objective response rate of 60% with a disease control rate of 90%.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n[\/vc_column_text][image_with_animation image_url=”2012″ image_size=”full” animation_type=”entrance” animation=”None” animation_movement_type=”transform_y” hover_animation=”none” alignment=”” img_link_large=”yes” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default”][vc_column_text]Two specific treatment cohorts were highlighted:<\/p>\n